Shares of Danish pharmaceutical company Novo Nordisk plummeted more than 15% during Monday trading after the company announced disappointing results from a clinical trial of its experimental obesity medication CagriSema, which failed to match the effectiveness of a competing drug from Eli Lilly.
The clinical study was intended to demonstrate that CagriSema could deliver weight reduction results comparable to Eli Lilly’s tirzepatide, but the trial did not achieve this objective, according to a company announcement.
The stock decline has eliminated approximately $400 billion from Novo Nordisk’s market value, bringing shares back to price levels not seen since before the successful launch of Wegovy transformed the company into the globe’s highest-valued pharmaceutical manufacturer. At its peak in 2024, the company was valued at over $600 billion.
During mid-morning trading in Copenhagen, Novo Nordisk’s stock price hit its lowest point since June 2021, coinciding with when the company first introduced its highly successful weight management medication to the market.
Financial analysts from J.P. Morgan characterized the trial failure as a major disappointment that could reduce interest in CagriSema, dampen future revenue projections, and make it challenging for Novo to regain competitive position in the rapidly expanding obesity medication sector.
“While CagriSema could offer a new treatment option to patients, the inferiority to Zepbound means it is unlikely to help Novo retake market share in obesity,” the analysts stated.
This development compounds existing investor concerns about escalating rivalry in the obesity treatment field, where consumer preference increasingly favors medications that deliver superior weight reduction outcomes.
Novo Nordisk ranked among the poorest-performing stocks on Europe’s primary STOXX 600 market index Monday. Zealand Pharma, another Danish pharmaceutical company, also experienced a 6.7% stock decline.
Meanwhile, Eli Lilly’s shares climbed approximately 4% during pre-market trading in the United States.
